Patents by Inventor Xun Ye
Xun Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287495Abstract: The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.Type: ApplicationFiled: May 22, 2023Publication date: September 14, 2023Inventors: Fang LIU, Liping LAN, Yutian WEI, Xun YE, Li ZHANG, Jiaqi HUANG, Yihong YAO
-
Patent number: 11697848Abstract: The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.Type: GrantFiled: January 21, 2019Date of Patent: July 11, 2023Assignee: Cellular Biomedicine Group, Inc.Inventors: Fang Liu, Liping Lan, Yutian Wei, Xun Ye, Li Zhang, Jiaqi Huang, Yihong Yao
-
Publication number: 20210214789Abstract: The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.Type: ApplicationFiled: January 21, 2019Publication date: July 15, 2021Applicants: SHANGHAI CELLULAR BIOPHAMACEUTICAL GROUP LTD., WUXI CELLULAR BIOPHAMACEUTICAL GROUP LTD.Inventors: Fang Liu, Liping Lan, Yutian Wei, Xun Ye, Li Zhang, Jiaqi Huang, Yihong Yao
-
Publication number: 20190236945Abstract: A vehicle alarm system includes at least one alarm transmitting device and at least one alarm receiving device. Each alarm transmitting device is disposed in at least one first vehicle. The alarm transmitting device includes a satellite positioning system. The alarm transmitting device of the first vehicle generates an alarm signal and wirelessly transmits an alarm signal. The alarm signal includes a destination signal and a vehicle coordinate signal. The satellite positioning system generates the vehicle coordinate signal. The destination signal includes a coordinate of a destination. The first vehicle moves toward the destination. Each alarm receiving device is disposed in a second vehicle. The alarm receiving device of the second vehicle receives the alarm signal wirelessly. The alarm receiving device generates an alert signal according to the alarm signal.Type: ApplicationFiled: January 17, 2019Publication date: August 1, 2019Inventors: BO-XUN YE, CHIA-YUAN LIN, CHIH-HAO LEE
-
Patent number: 10072300Abstract: A kit for the prognosis of colorectal cancer, which includes reagents related in detecting the expression level of any one or more genes of the following five genes: BST1, as shown in SEQ ID NO:1; MGST1, as shown in SEQ ID NO:2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO:11 or 12; RCAN3, as shown in SEQ ID NO:13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO:23 or 24. The reagents are used to detect the expression level of any one or more of the above five genes in the preparation of a kit for the prognosis of colorectal cancer. The kit can be used to perform precise prognosis for a patient suffering from colorectal cancer, and has good clinical application prospects.Type: GrantFiled: May 20, 2014Date of Patent: September 11, 2018Assignee: BIOMERIEUXInventors: Xia Meng, Qinghua Xu, Xun Ye, Fang Liu, Fei Wu
-
Patent number: 9771621Abstract: The present invention relates to method and kit for performing a colorectal cancer assay. Especially a method including extracting total RNA from a peripheral blood sample obtained from a patient suspected of having or having colorectal cancer; contacting the total RNA, or cDNA or cRNA obtained from the total RNA, with one or more reagents specific for at least one target gene and no more than 100 target genes; and measuring the expression level of the at least one target gene and no more than 100 target genes. The at least one target gene and no more than 100 target genes includes one or more members selected from the group consisting of the KLRB1, KLRC2, KLRC3, KLRD1, KLRK1, CD247, RRAS2, SH2D1B, LCK, MRPS6, SPRY4, CYBB, DUSP2, PDE4D, SH2D2A, GZMB, INSR, ITGAM, VCAN, CD163, P2RY10, CD226, MRPL10, ITPRIPL2, CD2, and NUDT16 genes.Type: GrantFiled: July 18, 2016Date of Patent: September 26, 2017Assignee: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin, Fang Liu
-
Patent number: 9689041Abstract: The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.Type: GrantFiled: March 23, 2012Date of Patent: June 27, 2017Assignee: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Fang Liu, Xia Meng, Bruno Mougin
-
Publication number: 20160319371Abstract: The present invention relates to method and kit for performing a colorectal cancer assay. Especially a method including extracting total RNA from a peripheral blood sample obtained from a patient suspected of having or having colorectal cancer; contacting the total RNA, or cDNA or cRNA obtained from the total RNA, with one or more reagents specific for at least one target gene and no more than 100 target genes; and measuring the expression level of the at least one target gene and no more than 100 target genes. The at least one target gene and no more than 100 target genes includes one or more members selected from the group consisting of the KLRB1, KLRC2, KLRC3, KLRD1, KLRK1, CD247, RRAS2, SH2D1B, LCK, MRPS6, SPRY4, CYBB, DUSP2, PDE4D, SH2D2A, GZMB, INSR, ITGAM, VCAN, CD163, P2RY10, CD226, MRPL10, ITPRIPL2, CD2, and NUDT16 genes.Type: ApplicationFiled: July 18, 2016Publication date: November 3, 2016Applicant: BIOMERIEUXInventors: Xun YE, Fei WU, Qinghua XU, Xia MENG, Bruno MOUGIN, Fang LIU
-
Publication number: 20160304944Abstract: A method and kit for discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene having a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.Type: ApplicationFiled: June 30, 2016Publication date: October 20, 2016Applicant: BIOMERIEUXInventors: Xun YE, Fei WU, Qinghua XU, Xia MENG, Bruno MOUGIN
-
Patent number: 9422598Abstract: A method and kit for the prognosis of colorectal cancer where the method includes the steps of: a) obtaining a peripheral blood sample and extracting total RNA from the sample, b) contacting the total RNA with at least one reagent specific for at least one NK cell gene and no more than 25 specific reagents for 25 NK cell genes, c) determining the expression level of at least one and at most 25 NK cell genes to obtain an expression profile for the patient, d) analyzing the expression profile with expression profiles previously clinically classified as a good prognosis and as a poor prognosis, wherein if the expression profile is clustered with the poor prognosis profiles, then the patient is determined to have a poor prognosis, and if the expression profile is clustered with the good prognosis profiles, then the patient is determined to have a good prognosis.Type: GrantFiled: June 4, 2010Date of Patent: August 23, 2016Assignee: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin, Fang Liu
-
Patent number: 9410188Abstract: A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.Type: GrantFiled: May 28, 2010Date of Patent: August 9, 2016Assignee: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin
-
Publication number: 20160177399Abstract: A kit for the prognosis of colorectal cancer, which includes reagents related in detecting the expression level of any one or more genes of the following five genes: BST1, as shown in SEQ ID NO:1; MGST1, as shown in SEQ ID NO:2, 3, 4, 5, 6, 7, 8, 9 or 10; HP, as shown in SEQ ID NO:11 or 12; RCAN3, as shown in SEQ ID NO:13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and SRA1, as shown in SEQ ID NO:23 or 24. The reagents are used to detect the expression level of any one or more of the above five genes in the preparation of a kit for the prognosis of colorectal cancer. The kit can be used to perform precise prognosis for a patient suffering from colorectal cancer, and has good clinical application prospects.Type: ApplicationFiled: May 20, 2014Publication date: June 23, 2016Inventors: Xia MENG, Qinghua XU, Xun YE, Fang LIU, Fei WU
-
Publication number: 20140057802Abstract: The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.Type: ApplicationFiled: March 23, 2012Publication date: February 27, 2014Applicant: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Fang Liu, Xia Meng, Bruno Mougin
-
Publication number: 20130173077Abstract: A power switch of a processing device comprises a plurality of series-connected switching stages, with each switching stage comprising a plurality of parallel-connected switching devices and an inverter chain. The switching devices are coupled between a power supply input and a power supply output of the power switch. Each of the switching devices of a given one of the switching stages is driven by an output of a corresponding one of the inverters of the inverter chain of that stage. A control input of the first switching stage receives a control signal for controlling a state of the power switch, and a control input of each remaining switching stage is driven by a control output of an immediately preceding switching stage. The switching devices in one or more of the switching stages are configured to have different switching characteristics than the switching devices in at least one other stage.Type: ApplicationFiled: December 29, 2011Publication date: July 4, 2013Applicant: LSI CorporationInventors: Zu Xun Ye, Joseph Gerard Garofalo, Ming Chen, ChunXuan Pei, Xiaopeng Xie
-
Publication number: 20130072399Abstract: A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.Type: ApplicationFiled: May 28, 2010Publication date: March 21, 2013Applicant: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin
-
Publication number: 20130072401Abstract: A method and kit for the prognosis of colorectal cancer where the method includes the steps of: a) obtaining a peripheral blood sample and extracting total RNA from the sample, b) contacting the total RNA with at least one reagent specific for at least one NK cell gene and no more than 25 specific reagents for 25 NK cell genes, c) determining the expression level of at least one and at most 25 NK cell genes to obtain an expression profile for the patient, d) analyzing the expression profile with expression profiles previously clinically classified as a good prognosis and as a poor prognosis, wherein if the expression profile is clustered with the poor prognosis profiles, then the patient is determined to have a poor prognosis, and if the expression profile is clustered with the good prognosis profiles, then the patient is determined to have a good prognosis.Type: ApplicationFiled: June 4, 2010Publication date: March 21, 2013Applicant: BIOMERIEUXInventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin, Fang Liu
-
Patent number: D679958Type: GrantFiled: March 9, 2012Date of Patent: April 16, 2013Assignee: Simplehuman LLCInventors: Frank Yang, Tzu-Hao Wei, Di-Fong Chang, Po-Ling Huang, Myk Lum, Xun Ye